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[ABSTRACT] 
The onset of the 21st century witnessed a biopharmaceutical revolution in the 
treatment of inflammatory rheumatic diseases. The fast evolving use of biologics 
highlighted the need for developing registers at national and international levels, 
with the aim of collecting long-term data on patient outcomes. Many biologic 
registers have now been in existence over 15 years contributing to a wealth of data 
and providing robust and reliable evidence on the use, effectiveness and safety of 
these biologics. The unavoidable challenges posed with the continuous introduction 
of new therapies such as the biosimilars and new class of janus kinases (JAK) 
inhibitors, especially with respect to understanding their safety in the longer term, 
highlights the importance of taking full advantage of learning from what has been 
published with respect to established biologic therapies. This article discusses the 
role of biologic registers in bridging the evidence gap with clinical trial data, focusing 
on methodological aspects of registers, unique features and challenges while 
considering their role going forward.  
 
Introduction 
The discovery and introduction of biologic treatment represents one of the most 
significant advances in the field of rheumatology. For rheumatoid arthritis (RA), 
biologics have transformed what was for many an incurable and devastating disease, 
into one that can be fully controlled.1 Although multiple randomized clinical trials 
(RCTs) have demonstrated the efficacy of these therapies, the nature of RCT 
recruitment and short follow-up periods means that efficacy (i.e. how a drug 
performs under clinical trial conditions) may not directly translate into effectiveness 
(i.e. how it performs under standard clinical practice conditions). It was on this basis 
that within rheumatology, a number of biologic registers were established, such that 
further data ĨƌŽŵ “ƌĞĂů-ǁŽƌůĚ ?ƉƌĂĐƚŝĐĞĐŽƵůĚďĞĐĂƉƚƵƌĞĚĂŶĚƚŚŝƐĞǀŝĚĞŶĐĞŐĂƉ
bridged. This Perspectives article discusses unique features, differences in 
methodological approaches and challenges in both the capture of and analysis of 
observational drug data when addressing questions around drug usage and effects in 
populations.  It highlights key lessons learnt drawing examples from European 
registers while discussing potential future applications. 
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What Is A Biologics Register? 
 
Rheumatology has a long tradition of observational research.2 With the advent of 
biologic therapies for RA, many existing observational patient registers adapted their 
data collection to increase their focus on outcomes following exposure to biologic 
therapies.  In many countries, however, new national biologics registers were 
established with the primary goal of studying treatment outcomes following 
biologics (see Figure 1 for examples in Europe).  
 
In essence, a biologics register is an observational cohort study which includes 
capture of detailed data on exposure to biologic therapies, such as details of the 
underlying diagnosis, drug start and stop dates, as well as treatment outcomes. 
These outcomes might include disease activity, patient reported outcome measures 
(PROMS) such as the Health Assessment Questionnaire (HAQ), as well as the 
occurrence of new comorbidity or adverse events.  
 
Although a majority of registers capture data across all of these areas, they do differ 
in their design. For example, in the UK and Germany, bespoke new cohort studies 
were established which recruited patients at the point of starting their first biologic. 
Both registers also aimed to recruit a cohort of patients receiving conventional 
standard DMARDs (csDMARDs) as a comparator.  In the case of the UK, the BSRBR-
RA did not set out from the start to capture data from all patients receiving a 
biologic, but instead to set recruitment targets and then stop recruitment when 
these targets were reached. This design differs from those based in countries which 
adapted or developed patient registers. Examples for the latter include Sweden 
(ARTIS), Denmark (DANBIO) or Switzerland (SCQM), whereby the capture of biologic 
data is embedded within a larger national patient register which aims to capture 
outcome data on all patients with RA, regardless of whether they receive biologic 
therapies.  
 
Both approaches have their strengths and weaknesses but offer valuable sources of 
data on the effects of biologic therapies. Bespoke biologic registers have the 
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advantage of deep data capture particularly surrounding the occurrence and details 
of adverse events but due to the increased workload of capturing such data, are 
often not comprehensive in their patient capture. This is in contrast to patient care 
registers which can ensure capture of almost every patient with RA, and thus may 
have inbuilt comparison cohorts, but often must rely on external data sources, with 
variable outcome event details for capture of adverse events.  
 
The large sample sizes, long follow-up and real-life populations included in biologics 
registers, contrast the relatively small and select, homogeneous RCT populations, 
enabling better external validity.  Many registers also have the ability to link to a 
national death database, bio-repositories or have access to laboratory data, making 
them particularly suited to answering specific research questions.3 Selected 
examples of established RA biologics registers, their purpose, design and unique 
features are shown in Table 1.  
 
What Can We Learn About Biologic Therapies Using Biologics Registers? 
 
RCTs remain the benchmark for measuring the efficacy of new therapies. However, 
they restrict patient inclusion, usually in an attempt to recruit a homogenous group 
of patients and thus are not always representative of the cohort of patients who will 
eventually go on to receive biologic therapies.4,5 They are usually not powered to 
study the risk of less common outcomes, such as serious infection.  As recruitment 
and follow-up are usually over a short period of time, latent effects, such as the risk 
of malignancy, may not be observed. Also, they cannot be used to comment on how 
clinical practice evolves over time. These are areas where data from registers can 
complement what information is obtained from clinical trials. 
 
The Use of Biologics in Clinical Practice 
Early reports from the German and Dutch registers found that a majority of patients 
who were receiving TNF inhibitors (TNFi) for RA would not have been eligible for 
participation in clinical trials.4,5 This was explained by both a proportion of patients 
who were too ill or disabled to participate, but there was also a proportion of 
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patients whose disease was not active enough to be eligible. More recent data from 
the British register have shown that patients who start rituximab or tocilizumab as a 
first line biologic, as opposed to a TNFI, have higher frequencies of important co-
morbidities such as prior cancer or interstitial lung disease, conditions which often 
preclude participation in RCTs.6  A study from the Swiss Clinical Quality Management 
Programme for RA (SCQM-RA) register demonstrated that biologic DMARDs 
(bDMARDs) were more often prescribed as monotherapy to older patients with co-
morbidity, lower BMI, longer disease duration, more previous bDMARDs and higher 
disease activity.7 The study of register data over time has provided insights into 
secular changes in the use of biologics, demonstrating earlier use following fewer 
csDMARDs in patients with lesser amounts of disability and corticosteroid 
exposure.8,9  
 
Biologic Treatment Effectiveness 
It follows that if the patient populations receiving biologics differ from those in RCTs, 
it may be that the expected response rates to therapy also differ. In general, initial 
treatment responses are similar to those observed in clinical trials10 ?12 but registers 
can go beyond treatment response and analyse long-term treatment persistence,13 ?
15 areas which have not been or can be explored in clinical trials. On average, 50% of 
patients have discontinued their first biologic by 5 years, either for ineffectiveness or 
adverse events.13 Register data can also be used to compare between different 
biologic therapies. Data from the Danish DANBIO11 and the Italian GISEA registers16 
suggested that infliximab was associated with the lowest rates of treatment 
response, disease remission and drug survival; the highest rates of treatment 
response and disease remission were observed with adalimumab; the longest drug 
survival rates with etanercept.11  
 
The lack of head-to-head trials of the best second line treatments in RA also directed 
focus towards register data to compare outcomes among patients switching to 
different treatment options. The majority of evidence from register data, including 
the Spanish BIOBADASER17 and Swedish STURE,18 suggest that overall, response 
rates are lower and drug-retention rates decrease in patients receiving a subsequent 
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TNFi.  Response to a second TNFi may differ according to the reason for initial TNFi 
treatment failure.19 Swiss and British register data have shown rituximab to be more 
effective than switching to an alternative TNFi in RA patients with persistently active 
disease despite a TNFi, 20,21 a finding supported by a recent non-register 
observational study22 as well as a large RCT.23 These observations have formed a 
strong evidence-base for clinical decisions in routine clinical practice.  Although the 
majority of data to date focus on TNFi, biologics registers have also already provided 
information on the use of newer biologics emerging over the course of the 21st 
century, including rituximab, abatacept and tocilizumab, 24 ?28usually incorporated in 
existing registers or in newly-developed registers.  
 
In addition to describing and comparing biologic treatment responses, registers have 
also better described the nature of patients who achieve a good response with TNFi. 
Factors which have been identified as being associated with response to treatment 
include younger age,11 shorter disease duration,29 better functional status at the 
start of therapy,11,30,31 and non-smokers.30,32 ?35  Furthermore, where studied, most 
registers have confirmed better treatment responses among patients who start TNFi 
alongside methotrexate, even in the setting of previous methotrexate 
failure.10,13,31,36  However, across all of these examples, register data have shown 
that clinical data alone are not sufficient to predict which patients will have a good 
response, which has led to further biomarker studies in RA.37   
 
Safety of Biologic Therapies 
The very large sample sizes and longer follow-up periods of biologics registers have 
allowed an analysis of risk beyond that available from clinical trials. A majority of 
registers have confirmed a small but significant increase in the risk of serious 
infections early on in the course of TNFi therapy, which seems to decrease over time. 
38,39, 24,40,41,42  Further exploration of the data held within the German RABBIT 
register, suggests this effect is due to both the depletion of patients at high risk of 
infection from the cohort, but also improvements in disease activity and lesser 
steroid use among those who do respond and stay on therapy, this reducing their 
individual infection risk. 43  In addition, observational drug registers have enabled the 
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study of potential benefits of treatment with respect to safety outcomes i.e. the 
association between TNFi and a reduced risk of cardiovascular events in RA 
patients.44 A number of registers have also now published on the observed risk of 
cancer compared to patients receiving csDMARD therapies and have not confirmed 
an increased risk of solid organ cancer or lymphoma45 ?56 (see supplementary tables 
1-3). 
 
Furthermore, biologic drug registers have enabled the study of outcomes in 
populations excluded from trials e.g. those with previous cancer51,57 and the 
elderly.42  They have also been able to comment on the risk of exposure to TNFi and 
other biologics during pregnancy.58,59  The provision of further insights into the real-
world safety of biologic therapies represents one of the most valuable aspects of 
register data.  
 
 
Biologics Registers: Methodological Challenges 
 
Developing and running a register requires thorough logistical and methodological 
planning to ensure completeness of data recording and adequate administrative 
support.  
 
Patient recruitment and missing data 
Recruitment into a register can be active or passive.  Active recruitment presents 
more challenges since it involves an additional step and effort in the management of 
the patient, which when added to a busy clinic environment means that not all 
eligible patients may get recruited.  
 
In order to ensure successful development, maintenance or consistent contribution 
to a register, it is important to have motivated physicians with a genuine interest and 
belief in the value of clinical data collection for research.  Whereas often such 
contribution is completely voluntary, in some countries it is a mandatory duty to 
contribute a minimum amount of data (usually pre-specified on paper/electronic 
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forms) to biologics registers. The latter includes patient demographic and drug 
details, including adverse events and reasons for discontinuation.  However, in busy 
clinical settings, accurately completing even the minimum amount of information 
requested, can pose a real challenge.  This often leads to incomplete forms being 
submitted, which adds further to the administrative workload.  In this respect, site 
reimbursement for recruiting patients into a register may provide an incentive for 
doing so.  Passive recruitment is in theory simpler; however a potential challenge is 
the disconnection between the reporter and recorder as to why the data need to be 
captured.  This, in turn, could risk incomplete or missing data that are likely to be a 
mixture of missing co-variate data or missing outcomes.  
 
Actively encouraging registers to report the proportion of missing data especially 
when studying key outcomes is necessary and could motivate more complete data 
collection. Reducing the amount of missing data and improving the accuracy of the 
data collected is important for the quality of analyses and consequently the findings 
and conclusions made. For this, adequate administrative input, physician/collector 
encouragement and support, are crucial.  
 
Type of data collection and input 
Securing long-term and reliable funding to ensure register sustainability and having a 
robust, high-quality and ideally web-based platform for data input, access and 
extraction represent important challenges. The depth of data collected depends on 
the type of register and its design, dictated by the research question(s) under study.  
For example, some registers will include collection of data on patient and disease 
characteristics as well as treatment data and potential confounders.  The actual 
process of data collection will depend on whether outcomes are reported or 
captured independent of the prescriber or both.  
 
Many registers use data linkage as a useful way of enriching source data.  Data 
linkage allows for further validation of events reported from source data and ensures 
more complete data, depending on the source of the linked data.  It is particularly 
valuable when the linked data are in a mandatory national dataset, such as a 
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national death or cancer register. The ability to validate the events captured through 
a linked route will depend on the methods of the independent data source.  
 
Biologics Registers: Analytical Challenges 
 
Lack of randomization 
The lack of randomization in patient allocation to treatment in routine clinical 
practice leads to confounding by indication, whereby observed outcomes may be 
related to the indication itself rather than any exposure, and this, along with the 
absence of a control group and channelling bias, necessitate appropriate and often 
advanced statistical techniques (e.g. propensity scoring) when analysing data. It 
should be acknowledged though that even with advanced statistical methods, these 
biases cannot be fully overcome.  Confounding by indication often stems from 
clinical reasons driving treatment choice, as a result of physician and patient 
perceptions of disease severity, prognosis and treatment effect.  However, other, 
 ‘ĞǆƚƌĂŶĞŽƵƐ ? aspects including socio-economic factors also influence these 
decisions60 and this requires appropriate epidemiological design, careful selection of 
control groups and analytical techniques.60 
 
Time lag between first treatment exposure and eventual register analyses 
The time lag (delay) from input of the drug into the market and the time needed to 
accumulate enough outcome data on which to base valid analyses needs to be 
considered. The analytical challenge relates both to the accumulated patient 
exposure and event latency relating to the drug. Finally, the issues of incomplete or 
missing data, missing patients (e.g. lost to follow-up) and the power to detect rare 
events need to be carefully considered, as even the largest national registers may 
still not be powered to be able to measure the risk of very rare events, such as 
certain individual cancer types. The latter, in particular, represents one of the major 
benefits of using combined register data.46  
 
Pooled vs parallel analysis 
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A possible simple solution to the issue of low power within individual registers is 
data pooling or parallel analysis with meta-analysis. However, as a result of 
differences in the register designs, types of data collected, as well as differences in 
health care systems, geographical and population differences, careful consideration 
is necessary regarding the best way to approach this. Aside from inherent variations 
in patient characteristics (e.g. different genetic backgrounds), endemic diseases (e.g. 
tuberculosis, HIV), presence of co-morbid conditions and differences in access to 
biologics may affect disease severity at the onset of treatment and therefore the 
response to treatment.  Therefore, simple data pooling to examine outcomes may 
not be an appropriate approach to study drug safety or effectiveness.  Instead, 
parallel analysis of data may be more appropriate and insightful into differing 
factors.  Furthermore, and beyond the type and nature of data collected, ethical 
restrictions and patient consent may be a further obstacle to data sharing and 
pooled analysis.   
 
The recognition of these issues has resulted in the publication of points to consider 
by EULAR, when designing and establishing a biologics register (Box 1).61 The 
differences in recruitment patterns, data collected (items and definitions) and 
biologic prescribing across registers is an important issue when pooling data 
together for analysis.62  Subsequently, the EULAR Study Group for Registers and 
Observational Studies (RODS)62  specifically set out to compare differences between 
patients starting biologics across Europe. This study, which involved 14 European 
bDMARD registers, highlighted that differences in disease severity do exist at the 
start of therapy, but also highlighted the issue of a lack of a common data model 
across Europe and the need to work further on harmonizing data collection across 
registers.   In this sense, identifying a minimum core set of items to be collected is 
thus useful in providing a common platform for common data analysis across 
multiple registers. This forms the backbone for the EULAR Task Force on 
recommendations for the standardised content and structure of core data to 
facilitate patient care and observational research in RA.63 
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The ability to standardize data collection across registers can lead to better 
understanding of the reasons for heterogeneity in the results observed and 
discrepant conclusions from some registers3 as well as improving the interpretation 
and comparison of class and drug-specific risks.64  Existing initiatives involving pooled 
data analysis25,27,28 have provided insights not just regarding the influence of intrinsic 
patient (e.g. age) and disease (e.g. antibody status) characteristics but also to 
extrinsic factors such as geographical and other influences and variations in 
treatment practice.  The growing interest in pooling datasets together for common 
data analysis represents a potential future application of biologics registers that 
would increase their power and enable the provision of information on a more 
diverse patient population.65,66   
 
Figure 2 summarises important strengths and challenges of biologic drug registers. 
 
Making The Best Use Of Observational Drug Data 
 
Many of the challenges/limitations discussed will inevitably be present but this is 
acceptable as long as there is transparency in methodology and limitations of 
analysis used.67  It should be remembered that even discrepant findings can provide 
us with important information if study design, analysis and data reporting is given 
careful consideration.3,68 
 
Future and novel applications 
The emphasis of research questions and outcomes examined in biologics registers is 
changing over time, shifting from a focus on disease behaviour, improving disease 
activity and decreasing disability to treatment effectiveness in different disease 
groups69 and on individualising treatment e.g. which biologic to choose after a 
patient experiences an inadequate response or an adverse event with a TNFi.70 
Although to date the majority of biologics registers started with recruitment of RA 
patients, over the years register data have extended to include biologic use for other 
conditions e.g. ankylosing spondylitis and psoriatic arthritis, enabling the study of 
important outcomes in these disease areas too.71,72 
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Platform for newly-emerging therapies 
With up to 15 years of knowledge gained from biologic register data, this represents 
a platform for embarking on collection of data for biosimilars, new classes of 
biologics and other advanced therapies. Several national rheumatology societies 
have already produced position papers on the use of biosimilars recommending the 
registration of biosimilar-treated patients in registers for efficacy, safety and 
immunogenicity surveillance, following the strategy already ongoing for 
originators.73 ?76  
 
Bridging the effectivenessʹefficacy gap 
Attempting to bridge the gap between effectiveness-efficacy i.e. reducing discrepancies 
identified between effectiveness (real life) and efficacy (ideal circumstances) and when 
evaluating new treatments would maximize the information gathered. Clinical trial data 
help us understand efficacy without the effect of confounding factors; however, 
efficacy across trial populations may not translate into equal effectiveness in 
individual, real-world patients. With comparative effectiveness research becoming 
increasingly important, clinical trials are unlikely to provide answers to many 
important questions, in contrast to observational biologics register data.3 
Furthermore, biologic registers could be of value in studying subsets of the 
population not adequately studied in clinical trials and to address effectiveness 
including cost-effectiveness of 3rd and 4th line biologics compared to earlier use in 
the treatment pathway.  
 
Combined register-trial studies 
With randomization being the only reliable method of controlling for confounding 
factors and enabling accurate comparisons of treatment groups, clinical trials 
represent a strong foundation for evidence-based medicine.77 However, to run an 
adequately powered clinical trial requires high costs and this, along with other 
limitations, including the select population which may not represent average clinical 
practice patients are important problems. A possible solution would be to include a 
randomization module within a clinical register with unselected consecutive 
enrolment hence in a way making the best use of a prospective randomized trial 
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combined with a larger-scale clinical register.77 Such an approach represents a 
potentially more efficient and cost-effective future application of a register making it 
possible to obtain more accurate answers to questions that clinical trial data alone 
would not have been able to provide. 
 
Conclusions 
Biologic drugs have had a ground-breaking effect on the treatment of RA; yet, the 
future of RA and its treatment does not solely rely on these. The intensified 
treatments and treat-to-target approaches that characterise current times on the 
background of emerging new therapies, necessitate high vigilance and carefully 
conducted studies to assess safety profiles, efficacy and effectiveness. The 
establishment of several national biologic registers globally to understand real-world 
effectiveness and safety beyond that observed in RCTs, fills an important gap in the 
literature, enhancing our understanding on real-life aspects of these therapies, their 
impact on disease progression and long-term outcomes. Their rich repository of data 
will have an ongoing role in complementing clinical trial data. Although challenges 
remain, with advanced methodologies and new technologies on the horizon, their 
potential for novel uses remains promising.  
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Figure 1 (Timeline) European biologic registries in rheumatoid arthritis. The design and unique 
features of some of the larger European registries are summarized below (in alphabetic order): 
Antirheumatic Therapies in Sweden (ARTIS)47,789,50: Overseen by the Swedish Rheumatology 
Association and integrated into clinical practice. Allows linkage to external registries and multiple 
control groups. Includes data from two regional sub-registries (Southern Swedish Antirheumatic 
Therapy Group and Stockholm TNF Follow-up). The British Society for Rheumatology (BSR) 
Biologics Registry (BSRBR)79: Formed by an alliance between the BSR, the pharmaceutical industry 
and the University of Manchester. Initiated as a national prospective study that mandated registry 
enrolment for all biologic-treated patients. The BSRBR includes data from a parallel comparison group 
of patients with active rheumatoid arthritis (RA) treated with conventional DMARDs. It has external 
linkage with national mortality and malignancy registries. Danish National Biologic Registry 
(DANBIO)80: National quality of care registry designed to capture operational clinical data as part of 
routine care. Includes patients with RA, Psoriatic arthritis and ankylosing spondylitis followed 
longitudinally. Norwegian Disease-Modifying Antirheumatic Drug Registry (NOR-DMARD)81: Five-
centre registry covering approximately one-third of the population in Norway. Includes all DMARD 
prescriptions to patients with inflammatory arthropathies, including RA. RA-Observation of Biologic 
Therapy (RABBIT)51: Nationwide prospective cohort study with an internal control group of DMARD 
switchers; after discontinuation of biologic treatment, the patients contribute to a second control group. 
Swiss Clinical Quality Management Programme for RA (SCQM-RA)82: Longitudinal population-based 
cohort of patients with RA, supported by the Swiss Society of Rheumatology. Recruitment is solely 
undertaken by rheumatologists. Patients included in SCQM-RA have more severe disease and receive 
more biologic agents than do RA patients in the general Swiss population. AIR, AutoImmunity and 
Rituximab; ATTRA, Registry of patients treated with anti-TNF drugs; BIOBADASER, Base de Datos 
de Productos Biológicos de la Sociedad Española de Reumatología; BIOROSS, Russian national 
biologic registry; BioRx, Slovenian national biologic registry; DREAM, Dutch RA Monitoring 
registry; ERSBR, Estonian Society for Rheumatology Biologics Register; GISEA, Grupo Italiano di 
Studio Sulla Early Arthritis; HeRBT, Hellenic Registry for Biologic Therapies; HU-REGA, Hungarian 
Registry; HÜR-BIO, Hacettepe University Rheumatology Biologic Registry; ICEBIO, Iceland National 
Biologics Registry; LORHEN, Lombardy Rheumatology Network; MIRA, MabThera In RA; 
NARRAS, National Registry of Patients with RA; ORA, Orencia in RA; RABBIT, RA Observation of 
Biologic Therapy; RATIO, Research Axed on Tolerance of Biotherapies; REGATE, Longitudinal 
Study on Patients with RA and Study on Tolerance and Efficacy of Tocilizumab (also known as 
REGistry-RoAcTEmra); Reuma.pt, The Rheumatic Diseases Portuguese Register; ROB-FIN, National 
Register of Biologic Treatment in Finland; SCQM-RA, Swiss Clinical Quality Management 
Programme for RA.  
  
 
Table 1. Examples of biologic registries in RA, their purpose, design and unique features. 
 
REGISTRY COUNTRY PURPOSE DESIGN & UNIQUE FEATURES 
 
BSRBR79 United 
Kingdom 
Established by the British 
Society for Rheumatology 
(BSR) to monitor patients 
with rheumatic diseases on 
biologics and evaluate long-
term toxicity of these agents 
in clinical practice. 
Nationwide registry, formed by an alliance 
between the BSR, the pharmaceutical industry 
and the University of Manchester. Designed as 
a national prospective study with patient 
enrolment being an essential part of the 
prescribing process.  The registry includes 
recruitment and collection of data from a 
parallel comparison group of patients 
consisting of those with active RA treated with 
conventional DMARDs. It has external linkage 
with national mortality and malignancy 
registries.  
ARTIS47,78 Sweden Developed to provide data 
on patients on biologics 
following request by the 
Swedish Medical Product 
Agency to rheumatologists.  
National registry. Overseen by the Swedish 
Rheumatology Association and integrated into 
clinical practice. Allows for multiple control 
groups to be used and linkage to external 
registries. Includes data from two regional 
registries (SSATG and STURE). 
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RABBIT51 Germany Developed to assess the 
long-term safety of biologics 
agents.  
Nationwide prospective cohort study with an 
internal control group of DMARD switchers; 
after discontinuation of treatment with 
biologics, the patients contribute to a second 
control group. 
DANBIO80 Denmark Developed to assess 
treatment effectiveness, 
adverse events and quality 
of life.  Aimed to have 
clinical usefulness to 
rheumatologists during 
consultations, to improve 
quality of care. 
National quality registry. Designed to capture 
operational clinical data as part of routine 
care. Includes patients with RA, PsA and AS 
followed longitudinally.  
NOR-DMARD81 Norway To assess the effectiveness 
and safety of DMARDs in 
inflammatory arthropathies.  
Five-centre registry covering approximately a 
third of the population in Norway; includes all 
DMARD prescriptions to patients with 
inflammatory arthropathies including RA.  
SCQM-RA82 Switzerland Aims to improve quality of 
care for patients with RA 
through examination of 
outcomes in individual 
patients. 
Longitudinal population-based cohort of RA 
patients; supported by the Swiss Society of 
Rheumatology.  Recruitment is solely 
undertaken by rheumatologists. Patients 
included in SCQM-RA have more severe 
disease and receive more biologic agents 
compared to RA patients in the general 
population. 
AS=Ankylosing Spondylitis; BSR=British Society of Rheumatology; PsA=Psoriatic arthritis; 
  
 
 
Figure 2. Strengths and challenges of biologic registers.  
 
 
 
 
Box 1. EULAR points to consider when establishing biologic registries.  Adapted from Dixon 
et al., 201061 
 
Points to consider 
 
1. General (e.g. defining scientific questions, considering sample sizes, follow-up 
needed) 
2. Population to be targeted (e.g. defining eligibility criteria) 
3. Data items to be collected, treatment and the treated condition (e.g. identifying a 
minimum core set of variables to be collected) 
4. Data items to be collected, outcomes (e.g. ensuring outcomes are collected in a 
complete, robust and transparent manner) 
5. Follow-up methods (e.g. ensuring similar methods to the exposed and comparison 
cohorts) 
6. Data collection process and data collectors (e.g. defining who will be providing and 
entering data, defining and testing data capture and entry) 
7. Data handling and storage, ethical and legal considerations (e.g. ensuring security 
of patient-identifiable information and compliance with local legislation) 
 
 
  
